King Pharmaceuticals KG Fixed Maturities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:FixedMaturitiesContinuousUnrealizedLossPositionLessthan12MonthsAccumulatedLoss.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's fixed maturities, continuous unrealized loss position, less than 12 months, accumulated loss.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's fixed maturities, continuous unrealized loss position, less than 12 months, accumulated loss?
- King Pharmaceuticals (KG) reported fixed maturities, continuous unrealized loss position, less than 12 months, accumulated loss of $484K in Q1 2026.